Bullzeye FinancialAbbott India Ltd.
NSE: ABBOTINDIA · Healthcare
Q1 earnings show 17% EPS growth on modest revenue, dividend confirms cash strength, but weak recovery volume and bearish technicals cap…
Q1 FY27 delivered 17.1% EPS growth and 15.3% EBITDA growth on just 4.3% revenue growth, demonstrating operational leverage; interim dividend of ₹131/share and BOB Capital Markets Buy rating with 20.7% upside target signal management and analyst confidence.
Stock underperformed NIFTY by 4.3 percentage points over 12 months despite Q1 strength; recovery volume is only 28% of average, and bearish EMA stack (20>50>200) with price 12.7% below 52-week high suggests institutional conviction is absent.
Free: 5 Forecasts and 5 Debates a month. Log in with your mobile number.
-
Bullish 28 Sep 2026 → now Scores 28 Oct 2026₹26,740.00 → ₹26,740.00 0.0%
Every verdict and forecast here is dated and scored when it matures — right or wrong. The first scored results publish a month after launch.
How we score →